China Attention Deficit Hyperactivity Disorder Market Size & Outlook
Related Markets
China attention deficit hyperactivity disorder market highlights
- The China attention deficit hyperactivity disorder market generated a revenue of USD 212.7 million in 2023 and is expected to reach USD 341.1 million by 2030.
- The China market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, stimulants was the largest revenue generating drug type in 2023.
- Non-stimulants is the most lucrative drug type segment registering the fastest growth during the forecast period.
Attention deficit hyperactivity disorder market data book summary
| Market revenue in 2023 | USD 212.7 million |
| Market revenue in 2030 | USD 341.1 million |
| Growth rate | 7% (CAGR from 2023 to 2030) |
| Largest segment | Stimulants |
| Fastest growing segment | Non-stimulants |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Stimulants, Non-stimulants |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, China accounted for 1.5% of the global attention deficit hyperactivity disorder market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan attention deficit hyperactivity disorder market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 341.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Attention Deficit Hyperactivity Disorder Market Scope
Attention Deficit Hyperactivity Disorder Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | View profile | 652 | 9715 Key West Avenue, Rockville, MD, United States, 20850 | https://www.supernus.com |
| NeuroSense Therapeutics Ltd | View profile | 16 | 11 HaMenofim Street, Building B, Herzliya, Israel, 4672562 | https://www.neurosense-tx.com |
| Vital KSK Holdings Inc | View profile | 5326 | 1-1-12 Tsurumaki, Setagaya-ku, Japan, 154-0016 | http://www.vitalksk.co.jp |
| Mallinckrodt PLC Ordinary Shares - New | View profile | 2700 | College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 | https://www.mallinckrodt.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
China attention deficit hyperactivity disorder market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.85% in 2023. Horizon Databook has segmented the China attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The Chinese population is inclined toward the use of traditional herbal medicine for the treatment of ADHD due to fewer adverse effects than pharmacologic medication. Stimulant medications available in China for the treatment of ADHD include methylphenidate and dexamphetamine.
Local companies entering into licensing agreements with foreign organizations for the production & development of novel ADHD medicines is expected to boost the market in China. For instance, in December 2021, Ark Biopharmaceutical Limited and Commave Therapeutics, SA, signed a licensing agreement to develop, manufacture, and commercialize AZSTARYS in greater China.
Tris's specially formulated, extended-release liquid and chewable ADHD medications aim to address this treatment gap, providing innovative therapeutic choices for the underserved pediatric ADHD population in China and equipping healthcare professionals with enhanced tools for effective patient care.
Reasons to subscribe to China attention deficit hyperactivity disorder market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China attention deficit hyperactivity disorder market databook
-
Our clientele includes a mix of attention deficit hyperactivity disorder market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into China attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China attention deficit hyperactivity disorder market size, by non-stimulants, 2018-2030 (US$M)
China Attention Deficit Hyperactivity Disorder Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
